Solid Lipid Nano-Composition for Berberine Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for diabetes and dyslipidemia often have low bioavailability and high toxicity, failing to effectively reduce insulin resistance and regulate sugar levels in the blood.
Innovation Solution
A solid lipid nano-composition comprising berberine and cinnamonaldehyde, formulated using solid lipid nanotechnology, with specific ratios of components such as soy bean oil and lecithin, to enhance bioavailability and reduce insulin resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for diabetes and dyslipidemia are used, then insulin resistance reduction and glucose metabolism improvement are attempted, but bioavailability of bioactive compounds is insufficient leading to suboptimal therapeutic effects
Solution Approach 1:
The patent uses a composite lipid nanoparticle system combining multiple lipids (solid lipid, liquid lipid, phospholipid) to create a delivery vehicle that simultaneously improves bioavailability and therapeutic effectiveness of berberine and cinnamonaldehyde
Solution Approach 2:
The patent changes the physical state and size parameters of the drug delivery system by forming nanoparticles with controlled size distribution and lipid composition, thereby enhancing absorption and bioavailability of the bioactive compounds
2Quantity of substance
If solid lipid nanotechnology is used to enhance bioavailability, then therapeutic effectiveness is improved, but formulation complexity and manufacturing difficulty increase
Solution Approach 1:
The patent segments the formulation into distinct functional components (solid lipid for structure, liquid lipid for flexibility, phospholipid for stability) with defined ratio ranges, making the complex formulation systematic and manufacturable
Solution Approach 2:
The patent defines specific parameter ranges for lipid ratios and nanoparticle characteristics that balance bioavailability enhancement with formulation simplicity and manufacturing feasibility
Data Source
AI summary
The present invention relates to a composition effective in treating diabetes and dyslipidemia prepared according to the solid lipid nanotechnology from two natural phytochemical active ingredients: cinnamonaldehyde extracted from the Vietnamese cinnamon and berberine as a bioactive compound extracted from several plants, including a group of shrubs called Berberis. Via testing, all of the composition of the present invention has shown to have low toxicity and great bioavailability, reduced insulin resistance that allows the sugar level in blood to more effectively induce reduction of insulin, hyperglycolysis that aids the body in cellular sugar decomposition, reduced sugar production in the liver, carbohydrate decomposition slowed down in the intestines, and an increasing in the number of beneficial microbes in the intestines. The composition is effective in reducing the total cholesterol level (TC), and non-HDL-cholesterol, and has a tendency to reduce TG level.